CO6640211A2 - Composiciones del péptido a-beta y métodos - Google Patents

Composiciones del péptido a-beta y métodos

Info

Publication number
CO6640211A2
CO6640211A2 CO12173790A CO12173790A CO6640211A2 CO 6640211 A2 CO6640211 A2 CO 6640211A2 CO 12173790 A CO12173790 A CO 12173790A CO 12173790 A CO12173790 A CO 12173790A CO 6640211 A2 CO6640211 A2 CO 6640211A2
Authority
CO
Colombia
Prior art keywords
methods
beta peptide
peptide compositions
epitope
amyloid
Prior art date
Application number
CO12173790A
Other languages
English (en)
Inventor
Neil R Cashman
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44541581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6640211(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of CO6640211A2 publication Critical patent/CO6640211A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Abstract

La presente invenci¨®n reclama un epitopo novedoso de una prote¨ªna, de conformaci¨®n restringida, derivada del amiloide A¦Â, caracterizado por poseer una ¡°regi¨®n de nudillo¡± a donde se unen los anticuerpos as¨ª como composiciones de anticuerpos afines con este epitopo y sus m¨¦todos de uso para el tratamiento, prevenci¨®n y diagn¨®stico de la enfermedad de Alzheimer.
CO12173790A 2010-03-03 2012-10-03 Composiciones del péptido a-beta y métodos CO6640211A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31016710P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
CO6640211A2 true CO6640211A2 (es) 2013-03-22

Family

ID=44541581

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12173790A CO6640211A2 (es) 2010-03-03 2012-10-03 Composiciones del péptido a-beta y métodos

Country Status (17)

Country Link
US (3) US9216217B2 (es)
EP (2) EP2542571B1 (es)
JP (2) JP6190113B2 (es)
KR (1) KR101831459B1 (es)
CN (1) CN102858796B (es)
AU (1) AU2011223456A1 (es)
BR (1) BR112012022229A2 (es)
CA (1) CA2791538C (es)
CL (1) CL2012002438A1 (es)
CO (1) CO6640211A2 (es)
IL (1) IL221695B (es)
MX (1) MX341536B (es)
NZ (1) NZ602548A (es)
RU (1) RU2644335C2 (es)
SG (1) SG183854A1 (es)
WO (1) WO2011106885A1 (es)
ZA (1) ZA201206916B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341536B (es) 2010-03-03 2016-08-24 The Univ Of British Columbia * Epitopo y anticuerpos beta amiloide de oligomero especifico.
WO2013071267A1 (en) * 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease
TWI571207B (zh) 2011-06-26 2017-02-21 安麗托克斯公司 用於條件化動物飼料之寒冷天氣調配物
CN104380111B (zh) * 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
US20180326027A1 (en) * 2015-11-09 2018-11-15 The University Of British Columbia Epitopes in amyloid beta and conformationally-selective antibodies thereto
KR20180088828A (ko) * 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
CN108475298A (zh) 2015-11-09 2018-08-31 英属哥伦比亚大学 通过集体坐标偏置预测错误折叠的蛋白质表位的系统和方法
JP7452829B2 (ja) * 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN112839710A (zh) * 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
WO1997037228A1 (en) 1996-03-29 1997-10-09 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US6686443B1 (en) 2000-05-26 2004-02-03 The Regents Of The University Of California Chemical reagents for formation of disulfide bonds in peptides
ATE334998T1 (de) 2003-04-07 2006-08-15 Novetide Ltd Verfahren zur herstellung cyclischer peptide
EP1484336A1 (en) 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
IL169622A0 (en) 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
JP5102205B2 (ja) * 2005-07-13 2012-12-19 コイミュン インコーポレイテッド 触媒免疫グロブリン
AU2007223427A1 (en) 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CN101622276B (zh) 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
MX2011000134A (es) 2008-07-01 2011-04-05 An Vws De Staat Der Nederlanden Vert Door De Minister V Vacuna contra el intermediario de plegamiento amiloide.
US20100173828A1 (en) 2008-07-25 2010-07-08 Abbott Gmbh & Co. Kg Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
US8410243B2 (en) 2008-12-17 2013-04-02 The Governors Of The University Of Alberta Aromatic ether-containing fluorene monomers, processes for their preparation and polymerization thereof
CA2747811A1 (en) 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds
AU2011215970A1 (en) 2010-02-09 2012-09-20 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
MX341536B (es) 2010-03-03 2016-08-24 The Univ Of British Columbia * Epitopo y anticuerpos beta amiloide de oligomero especifico.
WO2013071267A1 (en) 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Also Published As

Publication number Publication date
JP6190113B2 (ja) 2017-08-30
JP2013524774A (ja) 2013-06-20
US9216217B2 (en) 2015-12-22
JP2016193914A (ja) 2016-11-17
NZ602548A (en) 2014-12-24
BR112012022229A2 (pt) 2016-07-05
KR101831459B1 (ko) 2018-04-04
MX2012010175A (es) 2012-11-23
AU2011223456A1 (en) 2012-10-18
RU2644335C2 (ru) 2018-02-08
ZA201206916B (en) 2014-03-26
MX341536B (es) 2016-08-24
RU2012139043A (ru) 2014-04-10
KR20130045850A (ko) 2013-05-06
EP2542571B1 (en) 2016-05-25
CA2791538A1 (en) 2011-09-09
CN102858796B (zh) 2016-05-11
EP2542571A1 (en) 2013-01-09
CN102858796A (zh) 2013-01-02
US20140314773A1 (en) 2014-10-23
US20160228522A1 (en) 2016-08-11
US9849165B2 (en) 2017-12-26
CA2791538C (en) 2019-04-16
EP3056510B1 (en) 2018-10-03
SG183854A1 (en) 2012-10-30
EP3056510A1 (en) 2016-08-17
US20130084283A1 (en) 2013-04-04
CL2012002438A1 (es) 2013-09-13
WO2011106885A1 (en) 2011-09-09
EP2542571A4 (en) 2013-07-31
JP6494565B2 (ja) 2019-04-03
IL221695B (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CO6640211A2 (es) Composiciones del péptido a-beta y métodos
CY1122278T1 (el) Αντι il-36r αντισωματα
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CL2017000310A1 (es) Anticuerpos anti tigit
CR20190445A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201690372A1 (ru) Азапиридоновые соединения и их применение
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
MD3261720T2 (ro) Anticorpi anti-Tau și utilizările acestora
WO2013033037A3 (en) Novel antiprion compounds
EA201691141A1 (ru) Соединения против ccr6
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА
CO6602134A2 (es) Proteinas de union a antigeno especificas para componente amiloide serico p
NI201200144A (es) Anticuerpos humanizados de il - 25
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
PE20151164A1 (es) Anticuerpos bmp-6
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4

Legal Events

Date Code Title Description
FC Application refused